# What is the status of the retatrutide TRIUMPH-OUTCOMES trial?

Updated 2026-10-15.

ClinicalTrials.gov NCT06383390 lists the retatrutide TRIUMPH-OUTCOMES trial as Phase 3 and Active, not recruiting, with no registry results posted. The record's latest update was posted on 8 October 2026. Its primary and overall study completion dates are both estimated as February 2029. These fields were read on 15 October 2026; estimated dates are not completed milestones.

| | |
| --- | --- |
| Registry entry | ClinicalTrials.gov NCT06383390, read 15 October 2026 |
| Study name | TRIUMPH-OUTCOMES |
| Substance | Retatrutide (ClinicalTrials.gov NCT06383390) |
| Phase and status | Phase 3; Active, not recruiting (record updated 8 October 2026) |
| Actual study start | 30 April 2024 (ClinicalTrials.gov NCT06383390) |
| Estimated primary and study completion | February 2029 (ClinicalTrials.gov NCT06383390) |
| Registry results | No results posted (record read 15 October 2026) |

TRIUMPH-OUTCOMES has a separate registry number: NCT06383390. The October 2026 ClinicalTrials.gov entry describes retatrutide Phase 3 research sponsored by Eli Lilly and Company; the record update was posted on 8 October 2026 (read 15 October 2026).

## What status does NCT06383390 record?

[ClinicalTrials.gov NCT06383390](https://clinicaltrials.gov/study/NCT06383390) records the retatrutide TRIUMPH-OUTCOMES study as Active, not recruiting and Phase 3. The record names Eli Lilly and Company as lead sponsor and gives an actual start date of 30 April 2024. Its latest update was posted on 8 October 2026; these fields were checked on 15 October 2026.

This trial-status entry belongs to [Peptides and Australian Law](/learn/peptides-and-australian-law). The [Schedule 4 explainer](/learn/peptides-and-australian-law/what-schedule-4-and-appendix-d-mean) concerns the separate scheduling record. The [tirzepatide PBAC decision](/learn/peptides-and-australian-law/tirzepatide-pbac-march-2026-status) concerns a committee recommendation rather than this trial entry.

## Are completion dates actual, and are registry results posted?

The retatrutide TRIUMPH-OUTCOMES record, [NCT06383390](https://clinicaltrials.gov/study/NCT06383390), gives February 2029 as the estimated date for both primary completion and overall study completion. Neither field is marked Actual. ClinicalTrials.gov shows no results posted for this entry in the record read on 15 October 2026, whose latest update was posted on 8 October 2026.

Giblin et al.'s [TRIUMPH design paper](https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.70209), first published on 15 October 2025, describes TRIUMPH-1 through TRIUMPH-4; its abstract does not report TRIUMPH-OUTCOMES results (*Diabetes, Obesity and Metabolism*, January 2026 issue). The [semaglutide PBAC decision](/learn/peptides-and-australian-law/semaglutide-pbac-november-2025-status) is a separate dated status record.

## Frequently asked questions

### What is the registry number for retatrutide TRIUMPH-OUTCOMES?

ClinicalTrials.gov identifies retatrutide TRIUMPH-OUTCOMES as [NCT06383390](https://clinicaltrials.gov/study/NCT06383390) (update posted 8 October 2026, read 15 October 2026).

### Does this registry entry post results?

No. [NCT06383390](https://clinicaltrials.gov/study/NCT06383390) posts no registry results for retatrutide TRIUMPH-OUTCOMES in the record read on 15 October 2026 (update posted 8 October 2026).

## Citations

- Giblin K, Kaplan LM, Somers VK, et al.. Diabetes, Obesity and Metabolism. 2026;28:83-93. TRIUMPH-1 through TRIUMPH-4: rationale and design; first published 15 October 2025. DOI: 10.1111/dom.70209

---

Canonical page: https://www.formlaboratories.com/learn/peptides-and-australian-law/retatrutide-triumph-outcomes-status

Form Laboratories - Perth-based research-use-only peptide supplier, shipping Australia-wide.

- Site guide for agents: https://www.formlaboratories.com/llms.txt
- Sitemap: https://www.formlaboratories.com/sitemap.xml
- Full catalogue: https://www.formlaboratories.com/shop
- Contact: hello@formlaboratories.com

All materials are supplied for laboratory research use only - not for human or veterinary use, and nothing on this site is medical advice.